Vaxart Inc (VXRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxart Inc (VXRT) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($94.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vaxart Inc for the company's overall valuation and market capitalisation.
Vaxart Inc - Cash Flow Conversion Efficiency Trend (1985–2025)
This chart illustrates how Vaxart Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vaxart Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxart Inc ranked by their cash flow conversion efficiency. Explore VXRT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fortinova Fastigheter AB Series B
ST:FNOVA-B
|
0.012x |
|
Central Proteina Prima Tbk
JK:CPRO
|
0.013x |
|
Softronic AB
ST:SOF-B
|
0.055x |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
-0.011x |
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
1.752x |
|
Chien Shing Harbour Service Co Ltd
TW:8367
|
0.042x |
|
PT Janu Putra Sejahtera Tbk
JK:AYAM
|
0.017x |
|
TMT Steel Public Company Limited
BK:TMT
|
0.160x |
Annual Cash Flow Conversion Efficiency for Vaxart Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of Vaxart Inc from 1985 to 2025. View Vaxart Inc (VXRT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $87.80 Million | $7.71 Million | 0.088x | +111.57% |
| 2024-12-31 | $58.92 Million | $-44.76 Million | -0.760x | +37.67% |
| 2023-12-31 | $57.80 Million | $-70.45 Million | -1.219x | -42.22% |
| 2022-12-31 | $110.60 Million | $-94.78 Million | -0.857x | -168.60% |
| 2021-12-31 | $187.53 Million | $-59.83 Million | -0.319x | -65.78% |
| 2020-12-31 | $123.40 Million | $-23.75 Million | -0.192x | +80.96% |
| 2019-12-31 | $12.95 Million | $-13.09 Million | -1.011x | +21.93% |
| 2018-12-31 | $11.24 Million | $-14.55 Million | -1.295x | -141.11% |
| 2017-12-31 | $18.70 Million | $-10.04 Million | -0.537x | -75.92% |
| 2016-12-31 | $46.20 Million | $-14.10 Million | -0.305x | -120.95% |
| 2015-12-31 | $69.50 Million | $-9.60 Million | -0.138x | -263.74% |
| 2014-12-31 | $86.90 Million | $-3.30 Million | -0.038x | +81.42% |
| 2013-12-31 | $68.00 Million | $-13.90 Million | -0.204x | -0.29% |
| 2012-12-31 | $68.20 Million | $-13.90 Million | -0.204x | +20.88% |
| 2011-12-31 | $58.87 Million | $-15.17 Million | -0.258x | -139.08% |
| 2010-12-31 | $60.57 Million | $39.93 Million | 0.659x | +932.93% |
| 2009-12-31 | $97.41 Million | $6.22 Million | 0.064x | +140.99% |
| 2008-12-31 | $121.38 Million | $-18.90 Million | -0.156x | +14.68% |
| 2007-12-31 | $146.53 Million | $-26.74 Million | -0.183x | +53.70% |
| 2006-12-31 | $111.39 Million | $-43.91 Million | -0.394x | +28.89% |
| 2005-12-31 | $161.83 Million | $-89.71 Million | -0.554x | -1903.87% |
| 2004-12-31 | $284.32 Million | $8.74 Million | 0.031x | +30.12% |
| 2003-12-31 | $319.32 Million | $7.54 Million | 0.024x | -59.11% |
| 2002-12-31 | $189.03 Million | $10.92 Million | 0.058x | -55.03% |
| 2001-12-31 | $187.21 Million | $24.05 Million | 0.128x | +1.35% |
| 2000-12-31 | $77.39 Million | $9.81 Million | 0.127x | -68.34% |
| 1999-12-31 | $58.20 Million | $23.30 Million | 0.400x | +19.22% |
| 1998-12-31 | $54.20 Million | $18.20 Million | 0.336x | +199.30% |
| 1997-12-31 | $75.70 Million | $-25.60 Million | -0.338x | -569.63% |
| 1996-12-31 | $86.10 Million | $6.20 Million | 0.072x | -19.40% |
| 1995-12-31 | $69.40 Million | $6.20 Million | 0.089x | +1025.53% |
| 1994-12-31 | $51.80 Million | $-500.00K | -0.010x | -105.79% |
| 1993-12-31 | $18.00 Million | $3.00 Million | 0.167x | -20.11% |
| 1992-12-31 | $13.90 Million | $2.90 Million | 0.209x | +1675.18% |
| 1991-12-31 | $15.10 Million | $-200.00K | -0.013x | -132.05% |
| 1990-12-31 | $12.10 Million | $500.00K | 0.041x | -85.68% |
| 1989-12-31 | $9.70 Million | $2.80 Million | 0.289x | +1097.94% |
| 1988-12-31 | $8.30 Million | $200.00K | 0.024x | -81.63% |
| 1986-12-31 | $6.10 Million | $800.00K | 0.131x | -64.59% |
| 1985-12-31 | $2.70 Million | $1.00 Million | 0.370x | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more